Immuron & Monash University to develop a Clostridium difficile therapeutic
Advertisement
Immuron Limited has entered into a collaboration agreement with Monash University to develop a product or products that will be aimed at both prevention and treatment of Clostridium difficile (C. difficile) infections. The therapeutic will be based on Immuron’s hyper-immune colostrum platform technology, with its proven safety.
C. difficile infections have become a major medical problem especially in hospitals and long-term care facilities because the bacteria produce toxins that cause inflammation of the colon, causing severe diarrhoea and, in serious cases, death. An estimated 28,000 people die each year from these infections in the USA alone.
Monash University has received government funding through an ARC Linkage grant. As is typical with these grants, Immuron and Monash will together own the technology to be generated and Immuron has the exclusive global commercialisation rights.
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Bayer partners with innovative hormone monitoring device start-up - Funding to advance early-stage research efforts
Innovative device allows 3-D imaging of the breast with less radiation
Immune System Therapeutics completes $2.6 million placement
Eurofins expands its footprint in Asia with the acquisition of Lab Frontier in South Korea
Inimex Raises US $22 Million in the Fight Against Antibiotic Resistance
Mérieux Alliance Becomes Institut Mérieux - Alain Mérieux Confirms the Institute';s Commitment to Meeting new Medical and Public Health Challenges
Embion Technologies SA - Lausanne, Switzerland
DiaTech Srl - Jesi, Italy
GMS Gaswechsel-Messsysteme GmbH - Luckenwalde, Germany